Mesenchymal Stem Cells Emerge as Multi-Target Therapy for Alzheimer's Disease
A 2025 review maps preclinical and clinical evidence for MSC therapy in Alzheimer's, detailing mechanisms, limitations, and future directions.
Summary
This 2025 review in Regenerative Therapy synthesizes preclinical and clinical research on mesenchymal stem cell (MSC) therapy for Alzheimer's disease (AD). MSCs—sourced from bone marrow, adipose tissue, umbilical cord, and placenta—exert benefits through multiple mechanisms: reducing amyloid-beta and tau pathology, suppressing neuroinflammation, secreting neuroprotective factors like BDNF and NGF, regulating immune responses, and modulating signaling pathways such as AKT/IAP. Animal studies show improvements in cognitive function, reduced Aβ deposition, and decreased neuronal apoptosis. Compared to current drug and non-pharmacological treatments, MSC therapy offers multi-target action and neuroprotection, though challenges remain around cell survival, targeting, standardization, and cost. The review calls for further research to translate these promising preclinical findings into safe, effective clinical applications.
Detailed Summary
Alzheimer's disease (AD) affects an estimated 57 million people worldwide, with China alone accounting for 17 million cases and roughly 25% of global AD-related deaths. Current treatments—cholinesterase inhibitors, NMDA receptor antagonists, monoclonal antibodies, and non-pharmacological approaches—provide symptomatic relief but fail to halt or reverse disease progression. This landscape has intensified interest in regenerative strategies, particularly mesenchymal stem cell (MSC) therapy.
This 2025 narrative review by Feng et al., published in Regenerative Therapy, comprehensively surveys the preclinical and clinical applications of MSCs in AD. The authors first outline AD pathogenesis, emphasizing two hallmarks: extracellular amyloid-beta (Aβ) plaques formed via sequential cleavage of amyloid precursor protein (APP) by β- and γ-secretases, and intracellular neurofibrillary tangles (NFTs) arising from hyperphosphorylation of tau protein at sites including Ser199, Ser422, Thr205, and Thr231. Additional contributors include oxidative stress, vascular disease, heavy metal dysregulation, and genetic factors such as PSEN1, PSEN2, and APOE variants.
In preclinical models, MSCs derived from bone marrow, umbilical cord, adipose tissue, and placenta—as well as their conditioned media and extracellular vesicles (EVs)—demonstrated multi-pronged efficacy. Bovine umbilical cord MSC conditioned medium elevated BDNF and NGF while reducing IL-1β and TNF-α in AD rats. Bone marrow MSC-derived cytokines improved cognitive function and reduced Aβ deposition via AKT/IAP pathway regulation. Hematopoietic stem cell transplantation decreased Aβ accumulation and enhanced phagocytosis in AD animals. A detailed summary table catalogs MSC type, animal model, therapeutic effect, and mechanism across multiple recent studies, highlighting consistent findings of reduced neuroinflammation, enhanced synaptic plasticity, and improved cognitive outcomes.
The review also compares MSC therapy directly against pharmacological and non-pharmacological treatments in a structured table, noting MSC therapy's advantages of multi-target action, neuroprotection, immune regulation, and high safety profile. Disadvantages include unresolved issues around cell survival and CNS targeting, lack of standardized protocols, and high treatment costs—barriers that currently limit clinical translation.
The authors identify key mechanistic pathways by which MSCs exert their effects: paracrine secretion of neurotrophic factors, immunomodulation via suppression of pro-inflammatory cytokines, direct differentiation into neuronal lineages, and modulation of Aβ clearance pathways. Extracellular vesicles derived from MSCs are highlighted as a particularly promising cell-free alternative that may circumvent some safety and targeting concerns. The review concludes that while the preclinical evidence is compelling, rigorous clinical trials with standardized cell sources, doses, and delivery routes are urgently needed to establish MSC therapy as a viable AD treatment.
Key Findings
- MSC-derived conditioned media increased BDNF and NGF while reducing IL-1β and TNF-α in AD rat models.
- Bone marrow MSC cytokines improved cognition and reduced Aβ deposition via AKT/IAP pathway regulation.
- Hematopoietic stem cell transplantation enhanced Aβ phagocytosis and clearance in AD animal models.
- MSC extracellular vesicles represent a promising cell-free alternative with favorable safety and targeting profiles.
- Current drug treatments improve symptoms but cannot halt AD progression; MSCs offer multi-target neuroprotective potential.
Methodology
This is a narrative review synthesizing preclinical animal studies and early clinical data on MSC applications in AD. The authors compiled findings into structured summary tables comparing MSC types, animal models, therapeutic effects, and mechanisms. No systematic search protocol or meta-analytic statistical methods were reported.
Study Limitations
As a narrative review, it lacks a systematic literature search, inclusion/exclusion criteria, or risk-of-bias assessment, limiting reproducibility. Most evidence derives from animal models, and the full clinical trial data referenced in the paper's tables was truncated in the available text, making comprehensive evaluation of human evidence difficult.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.